Shegan Mahuang Decoction ameliorates pulmonary fibrosis progression by inhibiting CCL3-mediated NETosis
Phytomedicine · 2026-08 · 158 · 158386
DOI: 10.1016/j.phymed.2026.158386 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2026-08. Verfasst von Wencheng Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hang…. Hauptthemen laut MEDLINE: Pulmonary Fibrosis, Drugs, Chinese Herbal, Extracellular Traps. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Medical Science and Technology Project of Zhejiang Province, Science and Technology Program of Zhejiang Province.
Abstract (Originalsprache)
BACKGROUND Pulmonary fibrosis (PF) represents a spectrum of chronic lung disorders for which effective therapeutic options remain limited. Shegan Mahuang Decoction (SGMH) is a traditional Chinese medicine with potential therapeutic effects for respiratory system diseases. The precise mechanism of SGMH in treating PF has not yet been elucidated. PURPOSE This study aims to investigate the effectiveness and mechanism of SGMH in the treatment of PF. METHODS To investigate the effect of SGMH on PF, we established a mouse model and assessed inflammatory and neutrophil extracellular traps (NETs)-related markers. The target gene of SGMH was screened through integrated multi-omics analysis. The mechanisms of SGMH were explored through a series of experiments, encompassing NETs depletion with DNase I, the Pad4-/- mouse model, and pharmacological modulation via intraperitoneal administration of recombinant CCL3 (rCCL3) or a CCL3 neutralizing antibody (anti-CCL3). RESULTS SGMH ameliorated Bleomycin-induced lung tissue damage. It also inhibited pulmonary inflammation and NETs formation. Both DNase I-mediated NETs clearance and the Pad4-/- mice model showed that SGMH could not further ameliorate PF, indicating that SGMH blocks the PF development by inhibiting NETs formation. Multi-omics analysis and experimental validation found that SGMH inhibits NETs formation by targeting CCL3. Administration of rCCL3 restored NETs formation and attenuated the anti-fibrotic effect of SGMH. Moreover, treatment with anti-CCL3 alone inhibited PF, whereas its combination with SGMH did not further enhance the therapeutic effect. CONCLUSION This study demonstrated that SGMH ameliorates PF progression by inhibiting CCL3-mediated NETosis, suggesting its potential clinical application for PF treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310006, China; Clinical Pharmacy Teaching and Research Office, Sc…
- Department of Pharmacy, Zhejiang Hospital, Hangzhou 310013, China.
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, China; State Key Laboratory of Pharmaceutical Biotechnology and Nanjing Drum Tower Hospital School of Life Sci…
- State Key Laboratory of Pharmaceutical Biotechnology and Nanjing Drum Tower Hospital School of Life Sciences Chemistry and Biomedicine Innovation Center Nanjing University, Nanjing 210023, China.
- Department of Thoracic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China. Electronic address: lzclzc0928@foxmail.com.
- State Key Laboratory of Pharmaceutical Biotechnology and Nanjing Drum Tower Hospital School of Life Sciences Chemistry and Biomedicine Innovation Center Nanjing University, Nanjing 210023, China. Electronic address: quj…
Förderung
- National Natural Science Foundation of China
- Medical Science and Technology Project of Zhejiang Province
- Science and Technology Program of Zhejiang Province
- Jiangsu Province Natural Science Foundation
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Zhou, W., Wang, Z., Du, H., Zhao, W., Zhang, T., Liu, Z., Qu, J., & Sun, Y. (2026). Shegan Mahuang Decoction ameliorates pulmonary fibrosis progression by inhibiting CCL3-mediated NETosis. Phytomedicine, 158, 158386. https://doi.org/10.1016/j.phymed.2026.158386
Vancouver
Zhou W, Wang Z, Du H, Zhao W, Zhang T, Liu Z, et al. Shegan Mahuang Decoction ameliorates pulmonary fibrosis progression by inhibiting CCL3-mediated NETosis. Phytomedicine. 2026;158:158386. doi:10.1016/j.phymed.2026.158386
BibTeX
@article{Zhou2026,
author = {Zhou, Wencheng and Wang, Zhisen and Du, Haojie and Zhao, Wanjun and Zhang, Tao and Liu, Zhengcheng and Qu, Jiao and Sun, Yang},
title = {Shegan Mahuang Decoction ameliorates pulmonary fibrosis progression by inhibiting CCL3-mediated NETosis},
journal = {Phytomedicine},
year = {2026},
volume = {158},
pages = {158386},
doi = {10.1016/j.phymed.2026.158386}
}
EUVIMED